Concerns raised over NAFTA biologic data proposal

31-08-2018

Concerns raised over NAFTA biologic data proposal

Kerrick / iStockphoto.com

A proposal in the North American Free Trade Agreement (NAFTA) to set the length of biologic data exclusivity at ten years would harm patients, according to generic associations.


Biosimilar, biologics, generic drugs, branded drugs, North American Free Trade Agreement, drug pricing, affordable drugs, access to medicine

More on this story

Calls for NAFTA IP chapter to be abolished
26-01-2018

LSIPR